Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Phase Ib Trial with Dose Expansion of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab and Lenalidomide in Patients with Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Christian Grommes, MD, Anna Piotrowski, MD, Elena Pentsova, MD, Craig Nolan, MD, Jasmine Francis, Lisa DeAngelis, MD, Lauren Schaff, MD, Ingo K Mellinghoff, MD

Blood (2020) 136 (Supplement 1): 48.

https://doi.org/10.1182/blood-2020-143075

Published: 2020

Journal Articles

Phase II of Single-Agent Ibrutinib in Recurrent/Refractory Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL)

Christian Grommes, MD, Julia Wolfe, Igor Gavrilovic, MD, Thomas Kaley, MD, Jacqueline Stone, MD, Mariza Daras, MD, Craig Nolan, MD, Elena Pentsova, MD, Vaios Hatzoglou, MD, Ingo Mellinghoff, MD, Lisa DeAngelis, MD

Blood (2018) 132 (Supplement 1): 2965.

https://doi.org/10.1182/blood-2018-99-118538

Published: 2018

Journal Articles

Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-Conditioned Autologous Stem Cell Transplantation Are at a Higher Risk for DNA Virus Infections Than Patients with Systemic Non-Hodgkin Lymphoma Receiving Traditional Conditioning

Michael Scordo, MD, Sejal M. Morjaria, MD, Ankush Bhatia, MD, Eric R. Littmann, BA, Molly Maloy, MS, Lisa DeAngelis, MD, Sergio A. Giralt, MD, Ying Taur, MD MPH, Craig S. Sauter, MD

Blood (2017) 130 (Supplement 1): 4528.

https://doi.org/10.1182/blood.V130.Suppl_1.4528.4528

Published: 2017

Journal Articles

Single-Agent Ibrutinib in Recurrent/Refractory Central Nervous System Lymphoma

Christian Grommes, MD, Alessandro Pastore, MD, Igor Gavrilovic, MD, Thomas Kaley, MD, Craig Nolan, MD, Antonio M. Omuro, MD, Julia Wolfe, Elena Pentsova, MD, Vaois Hatzoglou, MD, Ingo Mellinghoff, MD, Lisa DeAngelis, MD

Blood (2016) 128 (22): 783.

https://doi.org/10.1182/blood.V128.22.783.783

Published: 2016

Journal Articles

Outcomes of Pharmacokinetically (PK) Directed Busulfan in Combination with Thiotepa & Cyclophosphamide (TBC) Conditioning with HDT-ASCT in Patients with Primary & Secondary CNS Lymphoma

Valkal Bhatt, PharmD, Michael Scordo, MD, Meier Hsu, MS, Antonio M. Omuro, MD, Lisa DeAngelis, MD, Andrew Lin, PharmD, Matthew J. Matasar, MD MS, Parastoo B. Dahi, MD, Craig H. Moskowitz, MD, Sergio A. Giralt, MD, Craig S. Sauter, MD

Blood (2015) 126 (23): 1994.

https://doi.org/10.1182/blood.V126.23.1994.1994

Published: 2015

Journal Articles

Phase I Study of Single Agent Ibrutinib in Recurrent/Refractory Primary and Secondary CNS Lymphoma

Grommes Christian, MD, Kaley Thomas, MD, Omar Abdel-Wahab, Antonio M. Omuro, MD, Mellinghoff Ingo, Lisa DeAngelis, MD

Blood (2015) 126 (23): 3960.

https://doi.org/10.1182/blood.V126.23.3960.3960

Published: 2015

Journal Articles

A Detailed Evaluation of Transplant-Related Toxicities and Outcome for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Using Thiotepa, Busulfan (Bu), Cyclophosphamide (TBC) Conditioning

Michael Scordo, MD, Valkal Bhatt, PharmD, Meier Hsu, MS, Antonio M. Omuro, MD, Matthew J. Matasar, MD MS, Lisa DeAngelis, MD, Parastoo B. Dahi, MD, Craig H. Moskowitz, MD, Sergio A. Giralt, MD, Craig S. Sauter, MD

Blood (2015) 126 (23): 4354.

https://doi.org/10.1182/blood.V126.23.4354.4354

Published: 2015

NARROW

Phase II of Single-Agent Ibrutinib in Recurrent/Refractory Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL)

Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-Conditioned Autologous Stem Cell Transplantation Are at a Higher Risk for DNA Virus Infections Than Patients with Systemic Non-Hodgkin Lymphoma Receiving Traditional Conditioning

Single-Agent Ibrutinib in Recurrent/Refractory Central Nervous System Lymphoma

Outcomes of Pharmacokinetically (PK) Directed Busulfan in Combination with Thiotepa & Cyclophosphamide (TBC) Conditioning with HDT-ASCT in Patients with Primary & Secondary CNS Lymphoma

Phase I Study of Single Agent Ibrutinib in Recurrent/Refractory Primary and Secondary CNS Lymphoma

A Detailed Evaluation of Transplant-Related Toxicities and Outcome for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Using Thiotepa, Busulfan (Bu), Cyclophosphamide (TBC) Conditioning

Email alerts

ASH Publications

American Society of Hematology

Phase II of Single-Agent Ibrutinib in Recurrent/Refractory Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL)

Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-Conditioned Autologous Stem Cell Transplantation Are at a Higher Risk for DNA Virus Infections Than Patients with Systemic Non-Hodgkin Lymphoma Receiving Traditional Conditioning

Single-Agent Ibrutinib in Recurrent/Refractory Central Nervous System Lymphoma

Outcomes of Pharmacokinetically (PK) Directed Busulfan in Combination with Thiotepa & Cyclophosphamide (TBC) Conditioning with HDT-ASCT in Patients with Primary & Secondary CNS Lymphoma

Phase I Study of Single Agent Ibrutinib in Recurrent/Refractory Primary and Secondary CNS Lymphoma

A Detailed Evaluation of Transplant-Related Toxicities and Outcome for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT) Using Thiotepa, Busulfan (Bu), Cyclophosphamide (TBC) Conditioning

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only